Meeting
2024 ASCO Annual Meeting
Identification of pharmaceutics with selective activity against melanoma-associated leptomeningeal disease using patient-derived circulating tumor cells.
Authors
Vincent Law
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Vincent Law , Simon Bayle , Derek R. Duckett , Peter A. J. Forsyth
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Brain Metastases
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 2032)
DOI
10.1200/JCO.2024.42.16_suppl.2032
Abstract #
2032
Poster Bd #
331
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Longitudinal single-cell (sc) immune profiling of cerebrospinal fluid (CSF) from melanoma patients (pts) with leptomeningeal disease (LMD) treated with intrathecal (IT) and intravenous (IV) nivolumab (N).
First Author: Golnaz Morad
Poster
2018 ASCO Annual Meeting
Role of melanoma cell-intrinsic RIG-I and STING signaling for checkpoint inhibitor‑mediated anticancer immunity.
First Author: Simon Heidegger
Poster
2014 ASCO Annual Meeting
Characterization of an anti-Τrop-2-SN-38 antibody-drug conjugate (IMMU-132) with potent activity against solid cancers.
First Author: David M. Goldenberg
Poster
2014 ASCO Annual Meeting
Effect of FGFR1 on epithelial-mesenchymal transition and EGFR resistance in HNC: A systems biology approach.
First Author: Damian Rieke